IP Library Granted Patent US 8,487,004
Granted Patent B2
US 8,487,004 · App. 13/524,590 · Granted Jul 16, 2013

Local treatment of neurofibromas

Inventors: Ruihong Chen (Foster City, CA); Allan E. Rubenstein (New York, NY); Xiaodong Shen (Foster City, CA); Scott Stewart (La Jolla, CA); Jin-Chen Yu (Palo Alto, CA)
Assignee: Nexgenix Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,487,004
App. No.
13/524,590
Granted
Jul 16, 2013
Kind
B2
Abstract

A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.

Claims (5)

1. A method of treating a dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma in a subject in need of such treatment, which method comprises locally administering a composition to the region of the tumor, wherein the composition comprises (a) one non-carcinogenic agent for treating the neurofibroma on the subject, and optionally (b) a pharmaceutically acceptable excipient that aids in transporting the non-carcinogenic agent into the tumor where it is preferably maintained for a sufficient period of time to treat the neurofibroma; wherein the non-carcinogenic agent is a non-steroidal anti-inflammatory (NSAID) agent.

2. The method of claim 1 , wherein said local administration is topically applying said composition to the surface of the skin in the region of the tumor, and wherein said excipient aids in transporting the agent across the skin and to the tumor and preferably maintains the agent on the skin of the subject.

3. The method of claim 1 , wherein said local administration is intralesionally injecting said composition into the tumor.

4. The method of claim 1 , wherein the excipient includes a skin penetrant.

5. The method of claim 1 , wherein the NSAID is diclofenac.

Assignments (4)
CHANGE OF NAME Recorded Sep 25, 2014
From: NEXGENIX PHARMACEUTICALS, LLC
To: NEXGENIX PHARMACEUTICALS HOLDINGS, INC.
Reel/Frame 033814/0407 →
CHANGE OF NAME Recorded Sep 25, 2014
From: NEXGENIX PHARMACEUTICALS HOLDINGS, INC
To: NEXGENIX PHARMACEUTICALS INC.
Reel/Frame 033814/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: NEXGENIX PHARMACEUTICALS INC.
To: ONCOSYNERGY, INC.
Reel/Frame 031145/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2013
From: CHEN, RUI-HONG; RUBENSTEIN, ALLAN E.; YU, JIN-CHEN; STEWART, SCOTT; SHEN, XIAODONG
To: NEXGENIX PHARMACEUTICALS INC.
Reel/Frame 030914/0111 →
Continuity (4)
Continuation 11815443
Provisional Application 60649854 · Feb 2, 2005
Provisional Application 60669813 · Apr 7, 2005
Related Publication 20120315298A1 · Dec 13, 2012